Please login to the form below

Not currently logged in
Email:
Password:

Dr Antoine Yver moves from AstraZeneca to Daiichi Sankyo

He becomes global head, oncology research and development

Daiichi Sankyo Dr Antoine YverDaiichi Sankyo has appointed Dr Antoine Yver to the newly-created position of global head, oncology research and development.

Reporting directly to Dr Glenn Gormley, Daiichi Sankyo's president and global head of research and development, Dr Yver will oversee the entirety of the firm's global research and development in the oncology therapeutic area.

Dr Gormley said: “Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients.

“We are confident that Antoine will provide great leadership and strategic insights in this new role, which underscores Daiichi Sankyo's commitment to the fight against cancer.”

Dr Yver moves from AstraZeneca, where he has served as senior vice president and head of oncology global medicines development as well as leading its global medicines development in China since 2012.

Prior to this, he has held senior management roles in oncology research at Aventis, Johnson & Johnson and Schering-Plough.

Dr Yver said: “I'm excited to join such a respected company and further build its presence in this important field.

“I have been most impressed by the quality of science at Daiichi Sankyo and the company's strong commitment towards becoming an innovator in bringing new therapeutic options to people living with cancer.”

6th April 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....